LOTA S ZOTH Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for LOTA S ZOTH.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of LOTA S ZOTH. LOTA S ZOTH is Chief Financial Officer in MEDIMMUNE INC /DE ($MEDI) and Director in INOVIO PHARMACEUTICALS, INC. ($GEB) and Director in NEWLINK GENETICS CORP ($NLNK) and Director in Orexigen Therapeutics, Inc. ($OREX) and Director in HYPERION THERAPEUTICS INC ($HPTX) and Director in Zymeworks Inc. ($ZYME) and CHIEF SCIENTIFIC OFFICER in Spark Therapeutics, Inc. ($ONCE) and Director in Spark Therapeutics, Inc. ($ONCE) and Director in 89bio, Inc. ($ETNB).
Latest Insider Trading Transactions of LOTA S ZOTH
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ETNB, HPTX, GEB, NLNK, MEDI, OREX, ONCE, ZYME
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 07 2021 | ZYME | Zymeworks Inc. | Zoth Lota S. | Director | Option Exercise | A | 29.49 | 9,000 | 265,410 | 9,000 | |
| Apr 19 2021 | ETNB | 89bio, Inc. | Zoth Lota S. | Director | Option Exercise | A | 24.16 | 12,500 | 302,000 | 12,500 | |
| Apr 19 2021 | ETNB | 89bio, Inc. | Zoth Lota S. | Director | Option Exercise | A | 24.16 | 12,500 | 302,000 | 12,500 | |
| Jun 16 2020 | ETNB | 89bio, Inc. | Zoth Lota S. | Director | Option Exercise | A | 24.05 | 20,000 | 481,000 | 20,000 | |
| May 15 2020 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | A | 0.00 | 8,700 | 0 | 8,700 | |
| May 15 2020 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | A | 13.65 | 13,300 | 181,545 | 13,300 | |
| May 12 2020 | ZYME | Zymeworks Inc. | Zoth Lota S. | Director | Option Exercise | A | 35.49 | 9,000 | 319,410 | 9,000 | |
| May 08 2020 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | M | 0.00 | 8,013 | 0 | 0 | |
| May 08 2020 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Buy | M | 0.00 | 8,013 | 0 | 12,103 | 4.1 K to 12.1 K (+195.92 %) |
| Apr 07 2020 | NLNK | LUMOS PHARMA, INC. | Zoth Lota S. | Director | Option Exercise | A | 7.78 | 5,684 | 44,222 | 5,684 | |
| Apr 07 2020 | NLNK | LUMOS PHARMA, INC. | Zoth Lota S. | Director | Grant | A | 0.00 | 709 | 0 | 1,820 | 1.1 K to 1.8 K (+63.82 %) |
| Jan 06 2020 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Grant | A | 0.00 | 2,100 | 0 | 10,006 | 7.9 K to 10 K (+26.56 %) |
| Jan 06 2020 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | M | 0.00 | 4,090 | 0 | 8,180 | |
| Jan 06 2020 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Buy | M | 0.00 | 4,090 | 0 | 4,090 | 0 to 4.1 K |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 37.18 | 12,000 | 446,160 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 37.18 | 12,000 | 446,160 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 56.22 | 6,000 | 337,320 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 56.22 | 6,000 | 337,320 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 50.93 | 4,000 | 203,720 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 50.93 | 4,000 | 203,720 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 81.53 | 4,000 | 326,120 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Option Exercise | D | 81.53 | 4,000 | 326,120 | 0 | |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Sell | U | 114.50 | 3,000 | 343,500 | 0 | 3 K to 0 (-100.00 %) |
| Dec 17 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | CHIEF SCIENTIFIC OF ... | Sell | U | 114.50 | 3,000 | 343,500 | 0 | 3 K to 0 (-100.00 %) |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 13,889 | 24,584 | 13,889 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 5.33 | 27,777 | 148,051 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 4,437 | 7,853 | 4,437 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 17.42 | 13,309 | 231,843 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 2,392 | 4,234 | 2,392 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 10.78 | 4,783 | 51,561 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 8,887 | 15,730 | 8,887 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 10.78 | 17,773 | 191,593 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 1,588 | 2,811 | 1,588 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 44.60 | 6,349 | 283,165 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 5,220 | 9,239 | 5,220 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 21.23 | 15,659 | 332,441 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 4,000 | 7,080 | 4,000 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 14.71 | 12,000 | 176,520 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 3,571 | 6,321 | 3,571 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 13.30 | 10,713 | 142,483 | 0 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.77 | 3,968 | 7,023 | 3,968 | |
| Aug 02 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | D | 13.30 | 11,904 | 158,323 | 0 | |
| Jun 03 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | M | 0.00 | 1,500 | 0 | 0 | |
| Jun 03 2019 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Buy | M | 0.00 | 1,500 | 0 | 3,000 | 1.5 K to 3 K (+100.00 %) |
| May 14 2019 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
| May 09 2019 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | A | 0.00 | 8,013 | 0 | 8,013 | |
| May 09 2019 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | A | 3.90 | 12,500 | 48,750 | 12,500 | |
| May 08 2019 | ZYME | Zymeworks Inc. | Zoth Lota S. | Director | Option Exercise | A | 19.11 | 10,000 | 191,100 | 10,000 | |
| Jan 04 2019 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | A | 0.00 | 12,270 | 0 | 12,270 | |
| Jan 04 2019 | GEB | INOVIO PHARMACEUTI ... | Zoth Lota S. | Director | Option Exercise | A | 4.28 | 20,000 | 85,600 | 20,000 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | M | 0.00 | 1,500 | 0 | 0 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | A | 0.00 | 1,500 | 0 | 1,500 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | A | 81.53 | 4,000 | 326,120 | 4,000 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Buy | M | 0.00 | 1,500 | 0 | 1,500 | 0 to 1.5 K |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | M | 0.00 | 1,500 | 0 | 0 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | A | 0.00 | 1,500 | 0 | 1,500 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | A | 81.53 | 4,000 | 326,120 | 4,000 | |
| May 31 2018 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Buy | M | 0.00 | 1,500 | 0 | 1,500 | 0 to 1.5 K |
| May 25 2018 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 5.33 | 27,777 | 148,051 | 27,777 | |
| Jul 18 2017 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 2.88 | 5,000 | 14,400 | 5,000 | |
| May 16 2017 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 17.42 | 13,309 | 231,843 | 13,309 | |
| Aug 11 2016 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 10.78 | 4,783 | 51,561 | 4,783 | |
| Aug 11 2016 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 10.78 | 17,773 | 191,593 | 17,773 | |
| Jul 14 2016 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 4.02 | 15,000 | 60,300 | 15,000 | |
| Jun 03 2016 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | A | 56.22 | 6,000 | 337,320 | 6,000 | |
| Jan 08 2016 | ONCE | Spark Therapeutics ... | Zoth Lota S. | Director | Option Exercise | A | 37.18 | 12,000 | 446,160 | 12,000 | |
| Jun 10 2015 | OREX | Orexigen Therapeut ... | Zoth Lota S. | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
| May 08 2015 | HPTX | HYPERION THERAPEUT ... | Zoth Lota S. | Director | Option Exercise | D | 327.95 | 55 | 18,037 | 0 | |
| May 08 2015 | HPTX | HYPERION THERAPEUT ... | Zoth Lota S. | Director | Option Exercise | D | 26.97 | 4,869 | 131,317 | 0 | |
| May 08 2015 | HPTX | HYPERION THERAPEUT ... | Zoth Lota S. | Director | Option Exercise | D | 24.46 | 14,700 | 359,562 | 0 | |
| May 08 2015 | HPTX | HYPERION THERAPEUT ... | Zoth Lota S. | Director | Option Exercise | D | 7.31 | 4,105 | 30,008 | 0 | |
| May 08 2015 | HPTX | HYPERION THERAPEUT ... | Zoth Lota S. | Director | Option Exercise | D | 1.28 | 11,855 | 15,174 | 0 | |
| May 08 2015 | HPTX | HYPERION THERAPEUT ... | Zoth Lota S. | Director | Sell | D | 46.00 | 2,617 | 120,382 | 0 | 2.6 K to 0 (-100.00 %) |
| May 04 2015 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Option Exercise | A | 44.60 | 3,643 | 162,478 | 3,643 | |
| May 04 2015 | NLNK | NEWLINK GENETICS C ... | Zoth Lota S. | Director | Grant | A | 0.00 | 1,962 | 0 | 7,906 | 5.9 K to 7.9 K (+33.01 %) |
| Mar 10 2004 | MEDI | MEDIMMUNE INC /DE | ZOTH LOTA S | Chief Financial Off ... | Option Exercise | A | 23.45 | 40,000 | 938,000 | 40,000 |
Page: 1